Máj- és epeúti rák: vizsgálatok itt: Kína
621 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1. fázisTaking peoplePersonalized DC Vaccine for Postoperative Cancer
- Where
- Chengdu
- Életkor
- 18 év to 100 év
- People
- 80
- Run by
- Sichuan University
See details and how to joinNCT04147078 - 2. fázisTaking peoplePhase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 33
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06852287 - 2. fázisTaking peopleCryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 25
- Run by
- Fudan University
See details and how to joinNCT04299581 - 2. fázisTaking peopleTACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 25
- Run by
- Fudan University
See details and how to joinNCT04954781 - 2. fázisTaking peopleLenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 25
- Run by
- Fudan University
See details and how to joinNCT05010681 - 2. fázisTaking peopleCryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 25
- Run by
- Fudan University
See details and how to joinNCT05057845 - No phaseTaking peopleNovel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 198
- Run by
- Zhongda Hospital
See details and how to joinNCT06849180 - No phaseTaking peopleDynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 332
- Run by
- Zhongda Hospital
See details and how to joinNCT06849193 - 2. fázisTaking peopleDEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 130
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT06397235 - 1. fázisNot yet taking people in KínaQL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 21
- Run by
- Wan-Guang Zhang
See details and how to joinNCT06822985 - No phaseNot yet taking people in KínaA Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC
- Where
- Dengzhou, Jiaozuo, Kaifeng, Luoyang, Shangqiu, Zhengzhou, Zhoukou
- Életkor
- 18 év to 80 év
- People
- 59
- Run by
- Xuhua Duan
See details and how to joinNCT06823050 - No phaseTaking peopleAmbispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 200
- Run by
- Tongji Hospital
See details and how to joinNCT05520788 - 2. fázisTaking peopleGOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence
- Where
- Hangzhou, Hanzhou
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT05557578 - 2. fázisTaking peopleLenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 35
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT05920863 - No phaseTaking peopleTACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 234
- Run by
- Third Affiliated Hospital, Sun Yat-Sen University
See details and how to joinNCT05984511 - 2. fázisTaking peopleLenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma
- Where
- Hangzhou
- Életkor
- 18 év to 85 év
- People
- 100
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT05532059 - No phaseTaking peopleStereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC
- Where
- Hangzhou
- Életkor
- 18 év to 80 év
- People
- 40
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT05596630 - 3. fázisTaking peopleLenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 80
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT05823311 - No phaseTaking peopleEarly-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
- Where
- Hangzhou
- Életkor
- 40 év to 75 év
- People
- 1608
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06139042 - No phaseTaking peopleStudy on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 100
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06542796 - No phaseTaking peopleHAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 300
- Run by
- Sun Yat-sen University
See details and how to joinNCT06333561 - No phaseTaking peopleChemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 300
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06718257 - 2. fázisTaking peopleHAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
- Where
- Fuzhou, Shanghai, Tianjin
- Életkor
- 18 év to 75 év
- People
- 165
- Run by
- Fudan University
See details and how to joinNCT06812039 - 3. fázisTaking peopleLenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 178
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT06492395 - No phaseNot yet taking people in KínaFusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular Carcinoma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 300
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT06798194